Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Chloe Atreya, MD, PhD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-353-9888
ORCID ORCID Icon0000-0003-2954-1727 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale UniversityMD, PhD2005School of Medicine
    Princeton UniversityBA1998
    University of California, San Francisco, CA11/2019Diversity, Equity, and Inclusion Champion Training
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    2011American Cancer Society Postdoctoral Fellowship 11-183-01-TBG
    2011Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
    2012Alliance for Clinical Trials in Oncology Foundation Investigator Award
    2014The Ernest H. Rosenbaum MD Commitment to Patient Care Award, UCSF Symptom Management Service
    2017The Marcus Program in Precision Medicine Innovation Seeding Bold Ideas Award
    2017Clinical Innovation Center Inside Out Accelerator Award

    Collapse Overview 
    Collapse Overview
    Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.

    Collapse Research 
    Collapse Research Activities and Funding
    Kinome-guided Targeting of Cooperative Dependencies in BRAF and KRAS Mutated Colorectal Cancer
    NIH/NCI R01CA229447Jun 1, 2019 - May 31, 2024
    Role: Principal Investigator
    (PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
    NIH/NCI R21CA227232Jun 21, 2018 - May 31, 2020
    Role: Co-Principal Investigator
    Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models
    NIH/NCI K08CA175153Sep 15, 2013 - Aug 31, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News
    Collapse Student Projects
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res. 2020 Feb 11. PMID: 32047001.
      View in: PubMed
    2. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020 Feb 07. PMID: 32031306.
      View in: PubMed
    3. Gonzalez A, Walker EJ, VAN Loon K, Cinar P, Atreya CE. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series. Anticancer Res. 2020 Feb; 40(2):865-871. PMID: 32014930.
      View in: PubMed
    4. Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial. Cancer Epidemiol Biomarkers Prev. 2020 Apr; 29(4):752-760. PMID: 31941707.
      View in: PubMed
    5. Le D, Kavan P, Kim T, Burge M, Van Cutsem E, Hara H, Boland P, Van Laethem J, Geva R, Taniguchi H, Crocenzi T, Sharma M, Atreya C, Diaz L, Liang L, Marinello P, Dai T, O'Neill B. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164. Ann Oncol. 2018 Jun; 29 Suppl 5:v107. PMID: 32176999.
      View in: PubMed
    6. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. PMID: 30058032.
      View in: PubMed
    7. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 Jan 01; 38(1):11-19. PMID: 31725351.
      View in: PubMed
    8. Rajaram S, Roth MA, Malato J, VandenBerg S, Hann B, Atreya CE, Altschuler SJ, Wu LF. A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors. Sci Data. 2019 10 31; 6(1):253. PMID: 31672976.
      View in: PubMed
    9. Silverstein J, Kidder W, Fisher S, Hope TA, Maisel S, Ng D, Van Ziffle J, Atreya CE, Van Loon K. Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period. Endocr Connect. 2019 Aug; 8(8):1149-1158. PMID: 31370007.
      View in: PubMed
    10. Thompson-Lastad A, Atreya CE, Chao MT, Pollak C, Dhruva A, Santana T, Abrams DI. Improving Access to Integrative Oncology Through Group Medical Visits: A Pilot Implementation Project. J Altern Complement Med. 2019 Jul; 25(7):733-739. PMID: 31314561.
      View in: PubMed
    11. Van Blarigan EL, Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya CE, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP. Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial. BMC Cancer. 2019 Mar 11; 19(1):218. PMID: 30866859.
      View in: PubMed
    12. Atreya CE, Venook AP. Of Microbes and Microsatellites. Cancer Immunol Res. 2018 11; 6(11):1290-1291. PMID: 30389718.
      View in: PubMed
    13. Dhruva A, Atreya CE, Chao MT. Applying New Models of Care to Meet Patient Needs in Integrative Oncology. J Altern Complement Med. 2018 Sep/Oct; 24(9-10):1010-1011. PMID: 30247958.
      View in: PubMed
    14. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. PLoS One. 2018; 13(7):e0199423. PMID: 30036361.
      View in: PubMed
    15. Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018; 8:13-23. PMID: 29628780.
      View in: PubMed
    16. Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 04; 8(4):428-443. PMID: 29431699.
      View in: PubMed
    17. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov. 2018 02; 8(2):164-173. PMID: 29196463.
      View in: PubMed
    18. Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ. Sampling strategies to capture single-cell heterogeneity. Nat Methods. 2017 Oct; 14(10):967-970. PMID: 28869755.
      View in: PubMed
    19. Parikh A, Atreya C, Korn WM, Venook AP. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2017 01; 15(1):3-8. PMID: 28040715.
      View in: PubMed
    20. Atreya CE, Yaeger R, Chu E. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. Am Soc Clin Oncol Educ Book. 2017; 37:246-256. PMID: 28561718.
      View in: PubMed
    21. Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw. 2016 12; 14(12):1536-1543. PMID: 27956538.
      View in: PubMed
    22. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. PMID: 28078110.
      View in: PubMed
    23. Atreya CE, Venook AP. Role of Biologics in Colon Cancer: Still Not Clear. J Oncol Pract. 2016 12; 12(12):1229-1230. PMID: 27943687.
      View in: PubMed
    24. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 05; 23(5):411-8. PMID: 27080472.
      View in: PubMed
    25. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. PMID: 26392102.
      View in: PubMed
    26. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333.
      View in: PubMed
    27. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol. 2015 Mar 01; 33(7):682-5. PMID: 25584005.
      View in: PubMed
    28. Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75. PMID: 25242168.
      View in: PubMed
    29. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. PMID: 23983256.
      View in: PubMed
    30. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS.Cancer Medicine. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. 2013.
    31. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506. PMID: 24156022.
      View in: PubMed
    32. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. PMID: 23542178.
      View in: PubMed
    33. Atreya CE, Ostrem JM, and Kelley RK.Personalized Medicine in Oncology. KRAS and Colorectal Cancer: Shades of Gray. 2012; 6(1).
    34. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9. PMID: 22393192.
      View in: PubMed
    35. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25. PMID: 22270257.
      View in: PubMed